Kindred Biosciences Inc. (KIN)
NASDAQ: KIN
· Real-Time Price · USD
9.25
0.01 (0.11%)
At close: Apr 24, 2025, 3:47 PM
Company Description
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets.
The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio.
Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates.
The company was founded in 2012 and is headquartered in Burlingame, California.
Kindred Biosciences Inc.
| Country | United States |
| IPO Date | Dec 12, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Dr. Richard Chin |
Contact Details
Address: 1555 Bayshore Hwy Ste 200 Burlingame, CALIFORNIA United States | |
| Website | http://www.kindredbio.com |
Stock Details
| Ticker Symbol | KIN |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001561743 |
| CUSIP Number | 494577109 |
| ISIN Number | US4945771099 |
| Employer ID | 46-1160142 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 14, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 13, 2021 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 13, 2021 | 4 | Filing |
| Sep 07, 2021 | 15-12B | Filing |
| Sep 01, 2021 | EFFECT | Filing |
| Aug 31, 2021 | SC 13D/A | [Amend] Filing |
| Aug 30, 2021 | 4 | Filing |
| Aug 30, 2021 | 4 | Filing |
| Aug 30, 2021 | 4 | Filing |